Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKCI | P41743 | 1/20 | 0.46 |
| ▸ | BRPF1 | P55201 | 2/20 | 0.43 |
| ▸ | HTR1D | P28221 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.41 |
| ▸ | CASP1 | P29466 | 3/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.40 |
| ▸ | MAPT | P10636 | 4/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | HBB | P68871 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31035937 | 1.00 | PRKCI (0.46) | PRKCIBRPF1HTR1DALDH1A1CASP1 | |
| SCHEMBL5985874 | 0.79 | KDM4E (0.41) | HTR1DALDH1A1KDM4EMAPTMEN1 | |
| SCHEMBL21001419 | 0.78 | PRKCI (0.44) | PRKCIBRPF1HTR1DALDH1A1KDM4E | |
| SCHEMBL29492232 | 0.78 | PRKCI (0.44) | PRKCIBRPF1HTR1DALDH1A1KDM4E | |
| SCHEMBL29263623 | 0.78 | PRKCI (0.44) | PRKCIBRPF1HTR1DALDH1A1KDM4E | |
| SCHEMBL15134029 | 0.78 | PRKCI (0.44) | PRKCIBRPF1HTR1DALDH1A1KDM4E | |
| SCHEMBL20562376 | 0.77 | HTR1D (0.50) | HTR1DALDH1A1KDM4EMAPTMAPK1 | |
| SCHEMBL2382103 | 0.76 | PDK1 (0.40) | MAPT | |
| SCHEMBL2112606 | 0.76 | KDM4E (0.59) | ALDH1A1KDM4EMEN1KMT2AL3MBTL1 | |
| SCHEMBL948433 | 0.76 | ALOX5 (0.44) | HPGDHTTLMNASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 108 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116332950-A | Indazole substituted podophyllotoxin derivative and preparation method and application thereof | 汤亚杰 | 2023-06-27 | — | — | CN | claimed |
| CN-116332950-A | Indazole substituted podophyllotoxin derivative and preparation method and application thereof | 汤亚杰 | 2023-06-27 | — | — | CN | disclosed |
| US-11072583-B2 | Indole (sulfomyl) n-hydroxy benzamide derivatives as selective HDAC inhibitors | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2021-07-27 | — | — | US | disclosed |
| WO-2020012424-A1 | SUBSTITUTED (AZA)INDOLE DERIVATIVES | RICHTER GEDEON NYRT. (HU) | 2020-01-16 | — | — | WO | disclosed |
| US-20190144398-A1 | METHOD FOR TREATING INFLAMMATORY DISORDERS | SYNTA PHARMACEUTICALS CORP. | 2019-05-16 | — | — | US | disclosed |
| US-20190144398-A1 | METHOD FOR TREATING INFLAMMATORY DISORDERS | SYNTA PHARMACEUTICALS CORP. | 2019-05-16 | — | — | US | disclosed |
| US-20170320837-A1 | METHOD FOR TREATING INFLAMMATORY DISORDERS | SYNTA PHARMACEUTICALS CORP. | 2017-11-09 | — | — | US | disclosed |
| US-20170320837-A1 | METHOD FOR TREATING INFLAMMATORY DISORDERS | SYNTA PHARMACEUTICALS CORP. | 2017-11-09 | — | — | US | disclosed |
| US-20170320837-A1 | METHOD FOR TREATING INFLAMMATORY DISORDERS | SYNTA PHARMACEUTICALS CORP. | 2017-11-09 | — | — | US | disclosed |
| EP-2298748-B1 | Triazole compounds that modulate HSP90 activity | SYNTA PHARMACEUTICALS CORP (US) | 2016-07-20 | — | — | EP | disclosed |
| US-20080004276-A1 | Method for treating non-hodgkin's lymphoma | LSI FINANCING LLC, AS ADMINISTRATIVE AGENT | 2008-01-03 | — | — | US | disclosed |
| US-20080004276-A1 | Method for treating non-hodgkin's lymphoma | LSI FINANCING LLC, AS ADMINISTRATIVE AGENT | 2008-01-03 | — | — | US | disclosed |
| WO-2007139952-A2 | METHOD FOR THE PREPARATION OF TRIAZOLE COMPOUNDS WITH HSP90 MODULATING ACTIVITY | SYNTA PHARMACEUTICALS CORP. (US) | 2007-12-06 | — | — | WO | disclosed |
| WO-2007140002-A2 | METHOD FOR TREATING NON-HODGKIN'S LYMPHOMA | SYNTA PHARMACEUTICALS CORP. (US) | 2007-12-06 | — | — | WO | disclosed |
| WO-2007139951-A2 | METHOD FOR TREATING PROLIFERATIVE DISORDERS ASSOCIATED WITH PROTOONCOGENE PRODUCTS | SYNTA PHARMACEUTICALS CORP. (US) | 2007-12-06 | — | — | WO | disclosed |
| CN-101072759-A | Triazole compounds that modulate hsp90 activity | SYNTA PHARMACEUTICALS CORP (US) | 2007-11-14 | — | — | CN | disclosed |
| EP-1817295-A1 | TRIAZOLE COMPOUNDS THAT MODULATE HSP90 ACTIVITY | Synta Pharmaceuticals Corporation (US) | 2007-08-15 | — | — | EP | disclosed |
| WO-2006055760-A9 | TRIAZOLE COMPOUNDS THAT MODULATE HSP90 ACTIVITY | SYNTA PHARMACEUTICALS CORP (US) | 2006-09-21 | — | — | WO | disclosed |
| US-20060167070-A1 | heat shock protein 90 inhibitors such as 3-(2-Hydroxyphenyl)-4-(naphthalen-1-yl)-5-mercapto-triazole, used for for preventing or treating hyperproliferative disorders, such as cancer | LSI FINANCING LLC, AS ADMINISTRATIVE AGENT | 2006-07-27 | — | — | US | disclosed |
| WO-2006055760-A1 | TRIAZOLE COMPOUNDS THAT MODULATE HSP90 ACTIVITY | SYNTA PHARMACEUTICALS CORP. (US) | 2006-05-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11072583-B2 | Indole (sulfomyl) n-hydroxy benzamide derivatives as selective HDAC inhibitors | HDAC1, HDAC3, HDAC2 | PRKCI 4049/4885BRPF1 1797/4885HTR1D 275/4885 |
| US-20080004276-A1 | Method for treating non-hodgkin's lymphoma | HSP90AB1, HSP90AB2P, HSP90B1 | PRKCI 1891/4885BRPF1 2949/4885HTR1D 4431/4885 |
| US-20190144398-A1 | METHOD FOR TREATING INFLAMMATORY DISORDERS | TNF, IL2, IL5 | PRKCI 2570/4885BRPF1 3852/4885HTR1D 4055/4885 |
| US-20170320837-A1 | METHOD FOR TREATING INFLAMMATORY DISORDERS | TNF, IL2, IL5 | PRKCI 2570/4885BRPF1 3852/4885HTR1D 4055/4885 |
| US-20060167070-A1 | heat shock protein 90 inhibitors such as 3-(2-Hydroxyphenyl)-4-(naphthalen-1-yl)-5-mercapto-triazole, used for for preventing or treating hyperproliferative disorders, such as cancer | HSP90AB1, HSP90AB2P, HSP90AA1 | PRKCI 652/4885BRPF1 1650/4885HTR1D 3576/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.